Literature DB >> 15557757

Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.

Manik C Ghosh1, Linda Grass, Antoninus Soosaipillai, Georgia Sotiropoulou, Eleftherios P Diamandis.   

Abstract

Human kallikrein 6 (hK6), a trypsin-like serine protease, is a newly identified member of the kallikrein gene family. Its involvement in inflammatory CNS lesions and in demyelination has been reported. Recent work has suggested that expression of this enzyme is significantly elevated in patients with ovarian cancer. We have identified many tumour cell lines that secrete hK6, but its physiological role is unknown. Here, we try to unveil the role of this kallikrein in the metastasis and invasion of tumour cells. We demonstrate that purified human recombinant hK6 can cleave gelatin in zymography and can efficiently degrade high-molecular-weight extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. In Boyden chamber assays, we found that tumour cells treated with a neutralizing hK6 antibody migrate less than control cells. We conclude that hK6 might play a role in the invasion and metastasis of tumour cells and may be a candidate therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557757     DOI: 10.1159/000081102

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

1.  LIN28B promotes colon cancer progression and metastasis.

Authors:  Catrina E King; Miriam Cuatrecasas; Antoni Castells; Antonia R Sepulveda; Ju-Seog Lee; Anil K Rustgi
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

3.  CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis.

Authors:  Teresina Laragione; Max Brenner; Barbara Sherry; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2011-11

4.  MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.

Authors:  Lizandra Jimenez; Ved P Sharma; John Condeelis; Thomas Harris; Thomas J Ow; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall
Journal:  Arch Pathol Lab Med       Date:  2015-07-14       Impact factor: 5.534

5.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

6.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16

Review 7.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

8.  The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts.

Authors:  Teresina Laragione; Max Brenner; Adriana Mello; Marc Symons; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2008-08

9.  Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Authors:  Rebecca S Henkhaus; Upal Kunal Basu Roy; Dora Cavallo-Medved; Bonnie F Sloane; Eugene W Gerner; Natalia A Ignatenko
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

10.  KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.

Authors:  N M A White; M Mathews; G M Yousef; A Prizada; C Popadiuk; J J E Doré
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.